Coronavirus Press Release
Allergy has published the second key paper on coronavirus disease, COVID-19.
Again the long term collaboration and know-how enabled this paper this time particularly aiming to help the doctors in daily patient care. The same team has published the first 140 cases of community acquired COVID disease and identified the reasons for severity almost 5 weeks ago. Prof. Akdis from SIAF and Prof. Gao from Wuhan act as senior authors of the new paper. Prof. Gao was working in Davos, Switzerland, but was called back to Wuhan when the outbreak became a public health problem. He is one of the proud doctors who had fought in the ward for two months for the success against coronavirus in Wuhan which decreased the number of new cases from 5000s per day to only a few per day. Prof Akdis says, “we aimed to describe, in this paper, the various clinical presentations of this disease by deeply examining eleven representative cases of its eleven faces. Clinical manifestations range from asymptomatic cases to patients with mild and severe symptoms, with or without pneumonia.”
Particularly, asymptomatic virus carriers and patients who clinically fully heal, but still carry the virus and may infect others represent two key groups to fully control the spread of the disease. Cases with pre-existing lung condition such as chronic obstructive lung disease and patients who develop secondary bacterial pneumonia represent the most severe cases. Patients with preexisting allergic diseases such as rhinitis, neurodermitis and urticaria did not develop a severe disease. The authors and many worldwide top scientists think that all different clinical characteristics of COVID-19 should be taken into consideration to identify patients for the efficient containment of the pandemic and to develop novel prevention and treatment strategies.
You can read the article here.
Allergy has published the first key paper on the coronavirus disease.
Wuhan University, Departments of Allergology, Respiratory and Critical Care Medicine and Radiology published together with the Swiss Institute of Allergy and Asthma Research (SIAF) the clinical characteristics of 140 patients infected by Wuhan Corona Virus (COVID-19) (here). The article appeared online today in Allergy, the official Journal of the European Academy of Allergy and Clinical Immunology. As of today, globally, 75,204 cases were confirmed, including 74,280 cases in China and 924 cases outside of China. 2006 patients have died from now officially named Severe Acute Respiratory Syndrome Coronavirus -2 infection.
The study reports randomly selected and community acquired 140 hospitalized COVID-19 cases. Male female ratio was 1:1 and median age was 57. None of the cases were related to Huanan wet market of wild animals. They were diagnosed by PCR test for the Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2). Main symptoms at admission were fever (91.7%), cough (75.0%), fatigue (75.0%), gastrointestinal symptoms (39.6%) and chest tightness or dyspnea (36.7%).
Hypertension (30.0%) and diabetes mellitus (12.1%) were the most common comorbidities. Since many of the severe virus infections take place in asthma and COPD patients, investigation of asthma, allergies and COPD were specifically focused. Interestingly, asthma, allergic rhinitis, atopic dermatitis, food allergy were not reported by any of the patients and COPD was only in 1.4 % of the patients. Asthma prevalence is 4.2 %, allergic rhinitis is 9.7 % and COPD is 13.7 % in the same age group in China, suggesting that Coronavirus pneumonia is not specifically selecting these patients. In addition, active smokers were only 1.4% of the COVID-19 cases which is the habit of 27.3 % of the individuals in China.
As a rapid diagnosis criteria before virus-specific tests are finalized, which may suggest immediate isolation of the patients, lymphopenia (75.4%) and eosinopenia (52.9%) were observed in patients. 58 of the 140 patients (41.4%) were severely affected in their lungs. Severe cases were elder patients, with more comorbidities, and with higher levels of acute phase reactants, CRP, procalcitonin and D-Dimer.
Editor in Chief of Allergy, Prof. Dr. Cezmi Akdis the Director of the Swiss Institute of Allergy and Asthma Research (SIAF) comments that this study reports the cases as detailed and as up to date as possible, which will be helpful to isolate the patients early enough to avoid the dissemination of the epidemics. Sharing detailed patient information as fast as possible with the public and scientific community will certainly help to inform the doctors to be prepared for early and rapid diagnosis of the suspected cases, taking the measures for patient isolation and identification of the severe cases.
The authors acknowledge all of the healthcare professionals, who helped and took care of the patients with COVID-19 for their great effort and their selfless dedication in the medical operation against SARS-CoV-2.
Cezmi Akdis
akdisac@siaf.uzh.ch
Editor in Chief of Allergy, Prof. Dr. Cezmi Akdis the Director of the Swiss Institute of Allergy and Asthma Research (SIAF) comments that this study reports the cases as detailed and as up to date as possible, which will be helpful to isolate the patients early enough to avoid the dissemination of the epidemics. Sharing detailed patient information as fast as possible with the public and scientific community will certainly help to inform the doctors to be prepared for early and rapid diagnosis of the suspected cases, taking the measures for patient isolation and identification of the severe cases.
The authors acknowledge all of the healthcare professionals, who helped and took care of the patients with COVID-19 for their great effort and their selfless dedication in the medical operation against SARS-CoV-2.
Cezmi Akdis
akdisac@siaf.uzh.ch
Obituary COVID-19
We dedicate this Issue of Allergy to the countless healthcare professionals who are putting their lives at risk every day in midst of the COVID-19 pandemic. Sadly, many doctors, nurses and healthcare professionals have passed away, particularly during the early days of the pandemic when there was limited personal protection equipment and missing awareness of the highly contagious nature of the virus.
COVID-19 has claimed the life of a large number of healthcare professionals, many are listed in our website and named in this picture. We would like that science and solidarity in the world prevails forever and that a scientific approach is always taken in any such threats to humanity.
Articles
Citations: 2721
Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)
Bousqet et al.
Citations: 2023
The global burden of asthma: executive summary of the GINA Dissemination Committee Report
Masoli et al.
Citations: 1189
A revised nomenclature for allergy - An EAACI position statement from the EAACI nomenclature task force
Johansson et al.
Citations: 673
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
Humbert et al.
Citations: 656
The EAACI/GA(2)LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
Zuberier et al.
Citations: 593
Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study
Jacobsen et al.
Citations: 519
A Prospective Study of Cow Milk Allergy in Danish Infants During the 1st 3 Years of Live - Clinical Course in Relation to Clinical and Immunological Type of Hypersensitivity Reaction
Host et al.
Citations: 497
Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis
Wilson et al.
Rewiring of gene networks underlying mite allergen‐induced CD4+Th‐cell responses during immunotherapy
Anya C. Jones et al.
Pilot study measuring transepidermal water loss (TEWL) in children suggests trilipid cream is more effective than a paraffin‐based emollient
Sayantani Sindher et al.
Transfer and loss of allergen‐specific responses via stem cell transplantation: a prospective observational study
Markus Debiasi et al.
Hypersensitivities following allergen antigen recognition by unconventional T cells
Marcela de Lima Moreira et al.
Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement
Bousqet et al.
Advanced forecasting of SARS-CoV-2-related deaths in Italy, Germany, Spain, and New York State
Sotgui et al.
Is global BCG vaccination-induced trained immunity relevant to the progression of SARS-CoV-2 pandemic?
Gursel et al.
March 2020 - Biologicals and Allergen Immunotherapy
Volume 75 | Issue 3
Special Issue: Perspectives in Allergen Immunotherapy: 2019 and Beyond
Volume 74 | Issue S108
Junior Members Corner
EAACI JMs come from all corners of the globe, and have been making significant contributions to the field of allergy. Read about some of their accolades here!
Letter to the JMs
The EAACI Annual Congress is coming up!
We have launched a quiz on the EAACI website: it is time to test your knowledge on allergy, immunology and… on our Academy! A winner is selected every month (2 in April) and the quiz is already available so, click here and do not miss the opportunity to win!
We look forward to hearing from you!
The Junior Member Assembly Board
We have launched a quiz on the EAACI website: it is time to test your knowledge on allergy, immunology and… on our Academy! A winner is selected every month (2 in April) and the quiz is already available so, click here and do not miss the opportunity to win!
We look forward to hearing from you!
The Junior Member Assembly Board
NAS-JM Translation Activities: sharing the Bulgarian experience
Education and information on medical sciences have never been as accessible as nowadays. This wealth of information is often communicated in English, which means a language barrier for some medical professionals. In that regard, the Junior Members of the Bulgarian Society of Allergology are contributing to the latest translation activities led by the National Allergy Societies Junior Committee (NAS-JM). Recently, 4 papers were translated into Bulgarian by a group of Junior members, who acted as translators and proofreaders. Then, junior representatives for the Spanish Society of Allergology Clinical Immunology (SEAIC) and the Spanish Society of Pediatric Allergy, Asthma and Clinical Immunology (SEICAP) helped at the typesetting stage.
The Bulgarian Society of Allergology is looking forward to publishing the translated papers on their National Allergy Society’s website, together with a printed version in Allergy, Hypersensitivity and Asthma, their official journal. This will increase the dissemination of the translated guidelines to all Bulgarian allergists. Importantly, the Bulgarian Society of Allergology has promised a small encouraging reward to all Junior Members who actively contribute to the translation activities, along with the recognition given by the Society in helping distribute with a “local voice” the latest EAACI guidelines, position papers, and innovations in allergy research.
The Bulgarian Society of Allergology is looking forward to publishing the translated papers on their National Allergy Society’s website, together with a printed version in Allergy, Hypersensitivity and Asthma, their official journal. This will increase the dissemination of the translated guidelines to all Bulgarian allergists. Importantly, the Bulgarian Society of Allergology has promised a small encouraging reward to all Junior Members who actively contribute to the translation activities, along with the recognition given by the Society in helping distribute with a “local voice” the latest EAACI guidelines, position papers, and innovations in allergy research.
